Study of a new injectable treatment for moderate-to-severe eczema
Treatments studied
Part of Skin clinical trials.
This trial tests an investigational drug called AK139, given as an injection, for people with moderate-to-severe atopic dermatitis (eczema). The goal is to reduce itching and clear skin better than current topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with atopic dermatitis (eczema) for at least 6 months.
- Your eczema must be moderate to severe, meaning it covers a large area and causes noticeable itching.
- You must have tried topical treatments (like prescription creams) and they didn't work well enough or you couldn't use them.
- You should not have taken certain strong medications (like oral steroids or immune-suppressing drugs) or light therapy in the last 4 weeks.
- You must agree to use effective birth control if you are able to have children, from the start of the study until 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called HXN5003 to see if it is safe and how well it works for people with moderate-to-severe eczema (atopic dermatitis). It may help reduce symptoms like itching and rash.
This study tests an investigational drug (SIM0278) given as an injection to see if it helps reduce eczema symptoms. It is for people with moderate to severe atopic dermatitis who have not used certain other treatments recently.
This trial tests a new medicine called AK120 for teenagers with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug can reduce itching and improve skin symptoms.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This trial tests an investigational drug called BxC-I17e, given as an injection under the skin, for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with standard creams. The goal is to see if it is safe and works well.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.